Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model

American Journal of Cardiology

Volumn 91, Issue 12, 2003, Pages 1427-1431

  Ryan Jr , Michael J ^a   Gibson, Joan ^b   Simmons, Phillip ^b   Stanek, Eric ^b  

^a Cardiovasc Risk Identification/T   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CERIVASTATIN; CHOLESTEROL; CYANOCOBALAMIN; FIBRIC ACID DERIVATIVE; FISH OIL; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY RISK; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPID ANALYSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038201862     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00393-X     Document Type: Article

References (18)

1. Bolton W.K. Nephrology nurse practitioners in a collaborative care model. Am J Kidney Dis. 31:1998;786-793.
2. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., Carney R.M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 333:1995;1190-1195.
3. DeBusk R.F. MULTIFIT a new approach to risk factor modification . Cardiol Clin. 14:1996;143-157.
4. Pollock M.L., Franklin B.A., Balady G.J., Chaitman B.L., Fleg J.L., Fletcher B., Limacher M., Pina I.L., Stein R.A., Williams M., Bazzarre T. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular diseasebenefits, rationale, safety, and prescription an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; position paper endorsed by the American College of Sports Medicine . Circulation. 101:2000;828-833.
5. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (Adult Treatment Panel III): full report. Bethesda, MD: NIH National Heart, Lung, and Blood Institute. 2001:1-284.
6. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith S.C. Jr, Alexander C.M., Londhe A., Lulla A., Simpson R.J. Jr. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
7. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals . Arch Intern Med. 160:2000;459-467.
8. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease principal results . Eur Heart J. 18:1997;1569-1582.
9. Brown A.S., Cofer L.A. Lipid management in a private cardiology practice (the Midwest Heart experience). Am J Cardiol. 85:(suppl):2000;18A-22A.
10. Shaffer J., Wexler L.F. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care . Arch Intern Med. 155:1995;2330-2335.
11. Wolfe M.L., Vartanian S.F., Ross J.L., Bansavich L.L.Mohler E.R. III, Meagher E., Friedrich C.A., Rader D.J. Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 87:2001;476-479.
12. Vacek J.L., Dittmeier G., Chiarelli T., White J., Bell H.H. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 76:1995;182-184.
13. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
14. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
15. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418.
16. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis a 4-year follow-up . JAMA. 264:1990;3013-3017.
17. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
18. Holmes C.L., Schulzer M., Mancini G.B.J. Angiographic results of lipid-lowering trials a systematic review and meta-analysis . Grundy S.M. Cholesterol-Lowering Therapy. Evaluation of Clinical Trial Evidence. 2000;191-220 Marcel Dekker, Inc, New York.